Edwards Lifesciences (EW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

EW · Stock Price

USD 83.20+8.57 (+11.48%)

Market Cap: $48.2B

Historical price data

Market Cap: $48.2BFounded: 1958Employees: 15,000-18,000HQ: Irvine, United States

Sector Ranking#14 in Drug Delivery & Formulation

Overview

Edwards Lifesciences is a patient-centric, global medical technology leader exclusively focused on structural heart disease solutions following its strategic 2024 divestiture of its Critical Care business. The company's mission is to deliver life-changing innovations, anchored by its dominant SAPIEN transcatheter aortic valve replacement (TAVR) platform, which has defined the standard of care. Its strategy involves reinvesting capital from the divestiture into R&D and clinical trials to expand indications, penetrate new geographies, and solidify its leadership in high-growth transcatheter mitral, tricuspid, and heart failure markets.

CardiovascularStructural Heart DiseaseHeart Failure

Technology Platform

Proprietary platforms for transcatheter heart valve replacement and repair (SAPIEN, PASCAL, EVOQUE), surgical tissue technology (RESILIA), and transcatheter shunt systems for heart failure (APTURE).

Funding History

1

IPOUndisclosedUndisclosedApr 15, 2000

Opportunities

Massive underpenetrated markets in transcatheter mitral, tricuspid, and heart failure therapies represent the next major growth frontier.

Geographic expansion, particularly in Asia-Pacific, and continued penetration into lower-risk aortic stenosis patients provide durable tailwinds for the core TAVR business.

Risk Factors

Clinical trial failures for key pipeline devices (EVOQUE, APTURE, SAPIEN M3) could impair growth.

Intensifying competition from Medtronic and Abbott, coupled with global healthcare pricing pressure, poses threats to market share and margins.

The company remains heavily reliant on its SAPIEN TAVR platform for the majority of revenue.

Competitive Landscape

Edwards dominates the TAVR market against Medtronic. In transcatheter mitral/tricuspid, it faces strong competition from Abbott's MitraClip in repair and a developing field in replacement. The surgical valve market is competitive with Medtronic, Abbott, and Artivion. Edwards' deep clinical evidence and physician relationships are key differentiators.